Clinical trials: Drug Eluting Stents
Coronary Artery Disease
The Efficacy of CILostazol ON Ischemic Complications After DES Implantation
Objectives : To evaluate the influence of concomitant use of cilostazol with aspirin and clopidogrel on the composite cardiovascular adverse outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion…
- Trial name
- CILON-T (NCT00776828)
- Testing
- cilostazol
- Where
- South Korea
- Volunteers
- 960 people
- Sponsor
- Seoul National University Hospital
Coronary Restenosis
Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES
Hypothesis: Angioplasty with a novel paclitaxel-coated balloon (PCB; Agent, Boston Scientific) with citrate-based excipient will be non-inferior to conventional paclitaxel-coated balloon with iopromide excipient (PCB) for the…
- Trial name
- ISAR-DESIRE 3A (NCT02367495)
- Testing
- PCB
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Chronic Total Occlusion of Coronary Artery
Drug-Coated Balloon Coronary Angioplasty Versus Stenting for Treatment of Disease Adjacent to a Chronic Total Occlusion.
This is an investigator-initiated, randomized, multi-center, non-inferiority clinical trial. Patients with a Chronic Total Occlusion who are eligible for PCI will be randomized to additional Drug-Coated-Balloon treatment or…
- Trial name
- Co-CTO (NCT04881812)
- Testing
- Drug-Coated Balloons, Drug-Eluting-Stent
- Where
- 2 sites in Netherlands
- Volunteers
- 144 people
- Sponsor
- Amsterdam UMC, location VUmc
Coronary Artery Disease
MIDCAB Versus DES in Proximal LAD Lesions
Percutaneous coronary intervention with a sirolimus-coated stent compared to minimally invasive bypass surgery in patients with isolated proximal left anterior descending coronary arteries in terms of non-inferiority of an end…
- Trial name
- NCT00299429
- Testing
- Stenting and minimally invasive bypass surgery, PCI with DES
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University of Leipzig
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl
Coronary Artery Disease, Coronary Thrombosis
Safety and Efficacy Study Comparing 3 New Types of Coronary Stents
Background: Retrospective analyses of long-term BASKET findings identified patients with large drug-eluting stents (DES) (>2.5mm Stents) as patients at risk for late cardiac death/nonfatal myocardial infarction.
- Trial name
- NCT01166685
- Testing
- Everolimus-eluting stent, Bare-metal stent, Biodegradable Polymer-DES
- Where
- 8 sites in Austria, Denmark and 2 more
- Volunteers
- 2,291 people
- Sponsor
- University Hospital, Basel, Switzerland
Coronary Artery Disease
Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation
The hypothesis to be tested is that gradual clopidogrel therapy cessation is associated with a superior clinical outcome compared with abrupt cessation (superiority hypothesis).
- Trial name
- ISAR-CAUTION (NCT00640679)
- Testing
- Abrupt Clopidogrel Interruption, Clopidogrel Tapering
- Where
- 2 sites in Germany
- Volunteers
- 782 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent
The success of stent implantation has led to the increasingly widespread use of them in the treatment of coronary artery disease (Sigwart, Serruys, Fischman)and although stent restenosis is still a limit for this therapeutic mode…
- Trial name
- EUCATAX (NCT00825279)
- Testing
- Bare Metal Stent, Drug Eluting Stent
- Where
- 2 sites in Argentina
- Volunteers
- 300 people
- Sponsor
- Centro de estudios en Cardiologia Intervencionista
Coronary Heart Disease, Stable Angina Pectoris
Heterogeneity of Neointimal Healing Following Biodegradable-polymer Drug-Eluting Coronary Stent Implantation
The objective of this study is a comparative evaluation of Orsiro stent and of Resolute Integrity stent in terms of the extent of neointima formation at 4 months after implantation using optical coherence tomography (OCT).
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- Healing (NCT04465669)
- Testing
- Orsiro stents, Resolute Integrity® stents
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Heart Diseases
Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study
The Galaxy First-in-man study is a small pilot. single arm research , which will enroll a total of 45 patients. The goal is to access the feasibility, safety and efficacy of Rapamycin Drug-Eluting Bioresorbable Coronary Stent…
- Trial name
- NCT02844270
- Testing
- Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Volunteers
- 45 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Coronary Artery Disease
Austrian Multivessel Taxus-Stent Registry
The aim of AUTAX study is to investigate the frequency of MACCE in patients with multivessel disease and multiple Taxus stent implantations in the "real world" stenting at 30 days, 6 and 12 months at 2 year follow-up.
- Trial name
- AUTAX (NCT00738686)
- Testing
- Intracoronary stent implantation
- Where
- 7 sites in Austria
- Volunteers
- 441 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease, Drug Eluting Balloon
Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two…
- Conditions
- Coronary Artery Disease, Drug Eluting Balloon, Drug Eluting Stent
- Trial name
- SPARX RCT (NCT07397845)
- Testing
- Protégé and Protégé NC, Agent, Drug Eluting Stent
- Where
- Switzerland
- Volunteers
- 1,380 people
- Sponsor
- Translumina GmbH
Elevated Lipoprotein(a) Level, Coronary Artery Disease
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
1. Main objective Among patients with elevated Lp(a) levels (>30mg/dL) who did not experience cardiovascular events or BARC type 2, 3, or 5 bleeding within 12 months after PCI and DES implantation, was it possible to reduce the…
- Conditions
- Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent, Dual Antiplatelet Therapy
- Trial name
- DAPT-Lp(a) (NCT06014060)
- Testing
- 24 Months DAPT, 12 Months DAPT
- Where
- China
- Volunteers
- 3,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease
ABSORB PHYSIOLOGY Clinical Investigation
The target enrollment goal for the trial was to enroll 36 subjects. However due to a challenging protocol inclusion/ exclusion criteria, only one subject was enrolled since the trial was initiated in June 2011.
- Trial name
- NCT01308346
- Testing
- Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS), XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- 6 sites in Australia, China and 2 more
- Volunteers
- 1 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES).
- Trial name
- MODEL U-SES (NCT02837003)
- Testing
- Aspirin, Thienopyridine
- Where
- Japan
- Volunteers
- 1,500 people
- Sponsor
- Teikyo University
Peripheral Arterial Disease, Arterial Occlusive Diseases
Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery
The purpose of this study is to evaluate whether the results of drug eluting balloon are non-inferior to the Nitinol stent implantation in the femoropopliteal segment.
- Conditions
- Peripheral Arterial Disease, Arterial Occlusive Diseases, Atherosclerosis, Arteriosclerosis
- Trial name
- PAVENST (NCT02212470)
- Testing
- Drug Eluting Balloon Angioplasty, Nitinol stenting
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
Myocardial Ischemia, Coronary Artery Stenosis
SPIRIT PRIME Clinical Trial
To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due…
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- SPIRIT PRIME (NCT00916370)
- Testing
- Core size Xience Prime, Xience Prime Long Lesion (LL)
- Where
- 62 sites in United States, Australia
- Volunteers
- 525 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Japan-Drug Eluting Stents Evaluation; a Randomized Trial
To evaluate the procedural, short and long term clinical outcomes of the TAXUS stent compared to Cypher stent in coronary arteries of ≥ 2.5 and ≤ 3.75 mm in the reference vessel diameter with a lesion of ≤ 46 mm (by visual…
- Trial name
- J-DESsERT® (NCT00708669)
- Testing
- TAXUS stent, Cypher stent
- Where
- 122 sites in Japan
- Volunteers
- 3,500 people
- Sponsor
- Associations for Establishment of Evidence in Interventions
Coronary Stenosis
Excel Drug-Eluting Stent Pilot Clinical Registry
The Trial aims to evaluate long-term efficiency of Excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.
- Trial name
- NCT00385905
- Testing
- Excel Drug-eluting stent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- JW Medical Systems Ltd